Research & Development
Our ability to develop and commercialize high-quality biosimilar insulins, monoclonal antibodies and conjugated recombinant proteins is driving a transformative shift in the treatment paradigm of life-threatening conditions for patients worldwide.
At our modern, state-of-the-art, integrated research centers located in Bengaluru and Chennai, we have lab to pilot scale capabilities, where innovative teams of experts work in fields ranging from bioengineering, molecular biology, analytical science, clinical science and regulatory science to intellectual property management.
Biocon Biologics’ regulatory strategies have benefited greatly from the experience of navigating an evolving landscape, as global regulatory agencies have gained confidence in delineating abbreviated approval pathways for biosimilars. With several successful filings and approvals of dossiers in ICH-regulated regions, we are established as a well-recognized, significant player in biosimilars, delivering a diverse and differentiated pipeline of therapeutics across the globe.
